Stemline Therapeutics, Inc. (STML)
-NasdaqCM | Prev Close: | 15.42 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 22.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 10.33 - 17.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 65,921 |
|---|
| Market Cap: | 118.35M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.58 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Stemline Therapeutics Announces Exercise of Option to Purchase Additional SharesGlobeNewswire(Thu, May 23)
- Stemline Therapeutics Announces Closing of $60 Million Public Offering of Common StockGlobeNewswire(Wed, May 22)
- STEMLINE THERAPEUTICS INC FinancialsEDGAR Online Financials(Tue, May 21)
- Stemline Therapeutics Prices $60 Million Public Offering of Common StockGlobeNewswire(Thu, May 16)
- STEMLINE THERAPEUTICS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- Stemline files to sell common stock, no amount givenat theflyonthewall.com(Mon, May 6)
- Post-IPO Strength Seen In Stemline Therapeuticsat Seeking Alpha(Thu, May 2)
- 3 Health Care Stocks Rising on Big Volumeat TheStreet(Mon, Apr 29)
- Stemline Therapeutics to Present at the 12th Annual Needham Healthcare Conference on May 1, 2013GlobeNewswire(Thu, Apr 25)
- Stemline Therapeutics, Inc. Announces Presentation of SL-401 Preclinical Efficacy in Multiple Myeloma at the 14th International Myeloma Workshop in Kyoto, JapanGlobeNewswire(Mon, Apr 8)
- STEMLINE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Mon, Apr 1)
- Stemline Therapeutics Reports Year-End 2012 Financial ResultsGlobeNewswire(Mon, Apr 1)
- STEMLINE THERAPEUTICS INC Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Apr 1)
- STEMLINE THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, Mar 29)
- Fuld Disclosureat The Wall Street Journal(Mon, Mar 25)
Reports
- No Reports available for STML at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-12)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-12)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk.
View More 
0.08%